Uveitis-Pipeline Review, H1 2018 by MarketResearchReports.biz
"The Report
Uveitis-Pipeline Review, H1 2018 provides information on pricing,
market analysis, shares, forecast, and company profiles for key
industry participants. - MarketResearchReports.biz"
About
Uveitis
Market
Global Markets Direct's latest
Pharmaceutical and Healthcare disease pipeline guide Uveitis -
Pipeline Review, H1 2018, provides an overview of the Uveitis
(Ophthalmology) pipeline landscape.
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/1672972
Uveitis is swelling and irritation
of the uvea, the middle layer of the eye. Uveitis can affect one or
both eyes. Uveitis can be caused by autoimmune disorders such as
rheumatoid arthritis or ankylosing spondylitis, infection, or
exposure to toxins. Symptoms include blurred vision, dark, floating
spots in the vision, eye pain, redness of the eye and sensitivity to
light. The predisposing factors include having an infection, an
autoimmune or inflammatory disorder and history of eye injury.
Treatment includes steroid eye drops, anti-inflammatory and
antibiotic or antiviral medication.
Report Highlights
Global Markets Direct's
Pharmaceutical and Healthcare latest pipeline guide Uveitis -
Pipeline Review, H1 2018, provides comprehensive information on the
therapeutics under development for Uveitis (Ophthalmology), complete
with analysis by stage of development, drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type. The
guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and
latest news and press releases.
The
Uveitis (Ophthalmology) pipeline guide also reviews of key players
involved in therapeutic development for Uveitis and features dormant
and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Pre-Registration, Phase III, Phase II,
Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 3, 6,
4, 1, 27 and 4 respectively. Similarly, the Universities portfolio in
Preclinical stages comprises 3 molecules, respectively.
Request
for TOC @
https://www.marketresearchreports.biz/reports/1672972/uveitis-pipeline-review-h1-2018-market-research-reports/toc
Uveitis (Ophthalmology) pipeline
guide helps in identifying and tracking emerging players in the
market and their portfolios, enhances decision making capabilities
and helps to create effective counter strategies to gain competitive
advantage. The guide is built using data and information sourced from
Global Markets Directs proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings,
investor presentations and featured press releases from
company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most
recent developments are captured on a real time basis.
Note: Certain content / sections
in the pipeline guide may be removed or altered based on the
availability and relevance of data.
Scope
- The pipeline guide provides a
snapshot of the global therapeutic landscape of Uveitis
(Ophthalmology).
- The pipeline guide reviews
pipeline therapeutics for Uveitis (Ophthalmology) by companies and
universities/research institutes based on information derived from
company and industry-specific sources.
- The pipeline guide covers
pipeline products based on several stages of development ranging from
pre-registration till discovery and undisclosed stages.
- The pipeline guide features
descriptive drug profiles for the pipeline products which comprise,
product description, descriptive licensing and collaboration details,
R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key
companies involved in Uveitis (Ophthalmology) therapeutics and
enlists all their major and minor projects.
- The pipeline guide evaluates
Uveitis (Ophthalmology) therapeutics based on mechanism of action
(MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates
all the dormant and discontinued pipeline projects.
- The pipeline guide reviews
latest news related to pipeline therapeutics for Uveitis
(Ophthalmology)
Reasons to buy
- Procure strategically important
competitor information, analysis, and insights to formulate effective
R&D strategies.
-
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive
advantage.
- Find and recognize significant
and varied types of therapeutics under development for Uveitis
(Ophthalmology).
- Classify potential new clients
or partners in the target demographic.
- Develop tactical initiatives by
understanding the focus areas of leading companies.
- Plan mergers and acquisitions
meritoriously by identifying key players and its most promising
pipeline therapeutics.
- Formulate corrective measures
for pipeline projects by understanding Uveitis (Ophthalmology)
pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing
and out-licensing strategies by identifying prospective partners with
the most attractive projects to enhance and expand business potential
and scope.
- Adjust the therapeutic portfolio
by recognizing discontinued projects and understand from the know-how
what drove them from pipeline.
View
Report @
https://www.marketresearchreports.biz/reports/1672972/uveitis-pipeline-review-h1-2018-market-research-reports
Table of Contents
Table of Contents 2
Introduction 4
Uveitis - Overview 5
Uveitis - Therapeutics Development
6
Uveitis - Therapeutics Assessment
16
Uveitis - Companies Involved in
Therapeutics Development 26
Uveitis - Drug Profiles 42
Uveitis - Dormant Projects 173
Uveitis - Discontinued Products
177
Uveitis - Product Development
Milestones 178
Appendix 188
List of Tables
Number of Products under
Development for Uveitis, H1 2018
Number of Products under
Development by Companies, H1 2018
Number of Products under
Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under
Development by Companies, H1 2018 (Contd..2), H1 2018
Number of Products under
Development by Universities/Institutes, H1 2018
Products under Development by
Companies, H1 2018
Products under Development by
Companies, H1 2018 (Contd..1), H1 2018
Products under Development by
Companies, H1 2018 (Contd..2), H1 2018
Products under Development by
Universities/Institutes, H1 2018
Number of Products by Stage and
Target, H1 2018
Number of Products by Stage and
Target, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and
Mechanism of Action, H1 2018
Number of Products by Stage and
Mechanism of Action, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and
Route of Administration, H1 2018
Number of Products by Stage and
Molecule Type, H1 2018
Uveitis - Pipeline by AbbVie Inc,
H1 2018
Uveitis - Pipeline by Aciont Inc,
H1 2018
Uveitis - Pipeline by Aldeyra
Therapeutics Inc, H1 2018
Uveitis - Pipeline by Apitope
International NV, H1 2018
Uveitis - Pipeline by Bionomics
Ltd, H1 2018
Uveitis - Pipeline by
Bristol-Myers Squibb Co, H1 2018
Uveitis - Pipeline by Clearside
BioMedical Inc, H1 2018
Uveitis - Pipeline by Coherus
BioSciences Inc, H1 2018
Uveitis - Pipeline by Elasmogen
Ltd, H1 2018
Uveitis - Pipeline by Endocyte
Inc, H1 2018
Uveitis - Pipeline by Enzo Biochem
Inc, H1 2018
Uveitis - Pipeline by EyeGate
Pharmaceuticals Inc, H1 2018
Uveitis - Pipeline by Eyevensys
SAS, H1 2018
Uveitis - Pipeline by F.
Hoffmann-La Roche Ltd, H1 2018
Uveitis - Pipeline by Galapagos
NV, H1 2018
Uveitis - Pipeline by HanAll
Biopharma Co Ltd, H1 2018
Uveitis - Pipeline by Icon
Bioscience Inc, H1 2018
Uveitis - Pipeline by Idera
Pharmaceuticals Inc, H1 2018
Uveitis - Pipeline by Johnson &
Johnson, H1 2018
Uveitis - Pipeline by Kv1.3
Therapeutics, H1 2018
Uveitis - Pipeline by Midatech
Pharma Plc, H1 2018
Uveitis - Pipeline by Mitotech SA,
H1 2018
Uveitis - Pipeline by Nemus
Bioscience Inc, H1 2018
Uveitis - Pipeline by Novartis AG,
H1 2018
Uveitis - Pipeline by OncoNOx ApS,
H1 2018
Uveitis - Pipeline by Ophthotech
Corp, H1 2018
Uveitis - Pipeline by Orchid
Pharma Ltd, H1 2018
Uveitis - Pipeline by Oxular Ltd,
H1 2018
Uveitis - Pipeline by Palatin
Technologies Inc, H1 2018
Uveitis - Pipeline by Panoptes
Pharma GesmbH, H1 2018
Uveitis - Pipeline by pSivida
Corp, H1 2018
Uveitis - Pipeline by Re-Pharm
Ltd, H1 2018
Uveitis - Pipeline by Santen
Pharmaceutical Co Ltd, H1 2018
Uveitis - Pipeline by Sun Pharma
Advanced Research Company Ltd, H1 2018
Uveitis - Pipeline by SynDevRx
Inc, H1 2018
Uveitis - Pipeline by TxCell SA,
H1 2018
Uveitis - Dormant Projects, H1
2018
Uveitis - Dormant Projects, H1
2018 (Contd..1), H1 2018
Uveitis - Dormant Projects, H1
2018 (Contd..2), H1 2018
Uveitis - Dormant Projects, H1
2018 (Contd..3), H1 2018
Uveitis - Discontinued Products,
H1 2018
About us
MarketResearchReports.biz is the
most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Comments
Post a Comment